This Regulated Generics Stock Rises 36% in 1 Year: Debt Down, Margins Up

This regulated generics stock rose approximately 36% in one year, from Rs 885.25 on 17 September 2025 to Rs 1,201.40 on 17 September 2026. The verified close to close return is 35.71%, with no split or bonus in the window.

The regulated generics stock is Strides Pharma Science Ltd (NSE: STAR), a Bengaluru based maker of oral solid and soft gelatin formulations sold into America, Britain, the Nordics and Africa. The Strides Pharma share price closed at a record Rs 1,217 on 10 September 2026, valuing the regulated generics stock at roughly Rs 10,955 crore.

Click Here – Get Free Investment Predictions

How Much Has This Regulated Generics Stock Returned in 1 Year?

The regulated generics stock returned 35.71% in the twelve months to 17 September 2026. Both dates were trading sessions, so no substitution was needed. This regulated generics stock was among the stronger names on a screen of NSE small-cap stocks ranked by 1-year return.

The path was ugly. The regulated generics stock fell to Rs 768.65 in late January 2026, below where the period started, then ran to Rs 1,231 by May. Shorter windows:

Period	Starting Close (Rs)	17 Sep 2026 (Rs)	Price Return
1 Month (17 Aug 2026)	987.10	1,201.40	21.7%
3 Months (17 Jun 2026)	1,106.90	1,201.40	8.5%
6 Months (17 Mar 2026)	875.45	1,201.40	37.2%
1 Year (17 Sep 2025)	885.25	1,201.40	35.7%

Three and five year returns are left out on purpose. The OneSource demerger of December 2024 pulled value out of the listed share, so unadjusted long-horizon numbers for this regulated generics stock mislead.

Why Did This Regulated Generics Stock Rise 36% in 1 Year?

Margins improved quarter after quarter while the balance sheet got lighter. Four dated events mark the re-rating.

1. Q2 FY26 Results on 31 October 2025

September 2025 quarter revenue was Rs 1,220.8 crore, up 4.6%, with EBITDA up 25% and the margin expanding 320 basis points to 19%. Operational profit rose 84% to Rs 140 crore.

The stock spurted about 15% that session to an all-time high of Rs 979. That is when the market stopped pricing a turnaround and started paying for margins.

2. FY26 Results on 18 May 2026

FY26 revenue was Rs 4,858.68 crore, up 6.42%, with EBITDA of Rs 925.3 crore at a 19% margin, up 140 basis points. Gross margin improved 310 basis points to 59.7% and operational profit rose 50.3% to Rs 518.1 crore.

The March 2026 quarter alone delivered revenue of Rs 1,323.47 crore, up 11.17%, and profit of Rs 126.94 crore, up 54.44%. A Rs 5 dividend followed, giving the regulated generics stock a second leg.

3. USFDA Clearance on 20 August 2026

The regulator inspected the flagship Bengaluru plant from 12 to 20 May 2026 and issued a Form 483 with five observations. On 20 August 2026 it issued an Establishment Inspection Report classifying the outcome Voluntary Action Indicated, the mildest closure category.

The regulated generics stock surged about 11% intraday to Rs 1,055.90 on that news. For a company shipping half its revenue into America, closing out the largest plant removes a supply risk.

4. The 12% Session on 7 September 2026

The regulated generics stock jumped as much as 12% intraday to Rs 1,185 on about 2.2 million shares, closing at Rs 1,178.80 against Rs 1,059.60. The annual report had just put markets outside America at 46% of revenue.

That mix shift is the durable part. Ex-United States revenue grew 21% in FY26 to Rs 2,240.4 crore while American revenue grew 2% to Rs 2,489.7 crore. Diversification lets this regulated generics stock compound when American pricing softens.

Check the Univest Screener for Live Fundamentals of High-Return Stocks

What the OneSource Demerger Did to the Chart

The OneSource demerger is why long-dated charts for this regulated generics stock look broken. The contract manufacturing and soft gelatin businesses were carved into OneSource Specialty Pharma, record date 6 December 2024, one OneSource share for every two Strides shares.

Cost of acquisition was split 89.35% to Strides and 10.65% to OneSource. The share went from around Rs 1,635 in late November 2024 to Rs 682.55 in the record-date week, value moving out rather than a collapse. OneSource listed on 24 January 2025.

Because the whole one year window sits after that event, the 36% figure for this regulated generics stock is clean. A second scheme effective 1 June 2026 moved a business of subsidiary Arco Lab to Pivot Path, with no entitlement for listed holders, though a Rs 100 crore gain sits in June quarter profit.

Strides Pharma Financials: Quarterly and Yearly

June 2026 quarter revenue was Rs 1,265.4 crore, up 13%, but EBITDA grew only about 5% to Rs 229.8 crore and the margin slipped 130 basis points to 18.2%. Management flagged roughly Rs 13.1 crore of freight cost and guided gross margin to a 58% to 60% band, the first wobble in the regulated generics stock story.

Metric	Q1 FY27 (Jun 2026)	FY26 (Full Year)
Revenue	Rs 1,265.4 Cr	Rs 4,858.7 Cr
Revenue Growth (YoY)	Up 13%	Up 6.4%
Gross Margin	60.9%	59.7%
EBITDA	Rs 229.8 Cr	Rs 925.3 Cr
EBITDA Margin	18.2%	19.0%
Operational PAT	Rs 123.1 Cr	Rs 518.1 Cr
Reported PAT	Rs 165.5 Cr	Rs 574.5 Cr
Net Debt	Rs 1,424.6 Cr	Rs 1,436.5 Cr

The longer arc is the real case for the regulated generics stock. Consolidated revenue went from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, while the bottom line swung from losses of Rs 474 crore and Rs 231 crore to a reported profit of Rs 574.5 crore.

Operating cash flow has stayed above Rs 680 crore for three straight years. On trailing earnings per share of Rs 68.83, the Strides Pharma share price near Rs 1,201 is 17.3 times earnings against an industry 37.4, with price to book 3.53 and return on equity 17.9%.

USFDA Status: Clean at Bengaluru, Three Observations at Alathur

The regulatory position is mixed, and holders of this regulated generics stock should carry both facts. Bengaluru is closed out at Voluntary Action Indicated. The Alathur plant near Chennai was inspected from 2 to 11 September 2026 and received a Form 483 with three observations the company must answer.

Scale cushions the regulated generics stock. The portfolio runs to 228 abbreviated new drug application filings with 210 approvals across 152 products. In America it has 72 commercialised products and is a top three supplier in 37, together about 70% of United States revenue.

Debt Reduction Is the Quiet Driver

Deleveraging has done as much for this regulated generics stock as any launch. Consolidated borrowings fell from roughly Rs 3,030 crore in FY23 to Rs 2,517 crore in FY24 and Rs 1,758 crore in FY26.

Net debt to EBITDA improved from 1.9 times to 1.55 times across FY26 and to 1.52 times by June 2026, and reported debt to equity fell from 1.32 in FY23 to approximately 0.57. Lower interest cost is why profit before tax grew faster than EBITDA, and it funded capital expenditure of Rs 417.94 crore in FY26.

Who Owns This Regulated Generics Stock

Institutions own more of this regulated generics stock than the promoters do, unusual for an Indian small cap. Foreign institutional investors held 28.40% and domestic institutions 15.42% in June 2026, against a promoter stake of 27.91%.

Shareholder	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	27.86%	27.86%	27.91%	27.91%
FIIs	28.51%	29.52%	28.68%	28.40%
DIIs	12.98%	13.02%	14.44%	15.42%
Public	30.62%	29.59%	28.96%	28.28%

Domestic institutions added roughly 244 basis points across four quarters while foreign holding drifted from its December 2025 peak. Promoters filed a disclosure on 7 April 2026 stating no promoter group shares were encumbered during FY26.

Key Risks in This Regulated Generics Stock

American pricing and product concentration: The United States is about half of revenue and grew 2% in FY26 and 4% in the June quarter. A top three position in 37 products delivering 70% of American sales means a few molecules carry the load, and new entrants have already compressed pricing on recent launches.

An open regulatory item: The Alathur Form 483 is unresolved. An adverse classification at any plant serving America can stall approvals and shipments, and the sector reprices that within a session.

Small-cap liquidity and volatility: At roughly Rs 10,955 crore of market capitalisation, the regulated generics stock trades like the small cap it is, swinging from Rs 768.65 in January 2026 to Rs 1,231 in May and back under Rs 950 in August, a 60% range inside eight months.

Back-ended launches: Management has said the first two quarters of FY27 will be soft, with the bulk of roughly ten planned launches in the second half, packing execution risk for the regulated generics stock into a short window.

A messy history: This regulated generics stock sat on losses in FY22, FY23 and FY24, and has been reshaped twice by schemes of arrangement in two years, which makes comparison hard.

Download the Univest iOS App or Univest Android App to track the Strides Pharma share price live

Strides Pharma Share: Analyst View

Coverage on the Strides Pharma share is thin for a company this size, and what is public is dated. Broker views compiled before the 18 May 2026 results clustered between Rs 1,080 and Rs 1,250. The Strides Pharma share price has run past that band.

What analysts following this regulated generics stock watch now is narrower: whether the second half of FY27 delivers the launches, whether the ex-America mix crosses half of revenue, and whether Alathur closes cleanly.

Strides Pharma Share Price Target

No brokerage Strides Pharma share price target published after the June 2026 quarter could be verified, so no forecast is offered for this regulated generics stock. The targets in circulation predate both the FY26 results and the August 2026 clearance.

Working from levels instead: the 52-week high is Rs 1,231 and the low Rs 768.65. The regulated generics stock near Rs 1,201 sits 2.4% below that high and 56% above the low. A trailing 17.3 multiple against an industry 37.4 leaves re-rating room, but only if FY27 earnings arrive.

A Strides Pharma share price target built on a stale estimate is not a plan. Judge this regulated generics stock against those 52-week levels and against quarterly delivery instead.

Other Stocks to Track From the Same Return Screen

Beyond this regulated generics stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Vijaya Diagnostic with a 1-year return of 43.04%, SPARC at 33.17% and Aether Industries at 113.84%.

Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this regulated generics stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.

Conclusion

This regulated generics stock earned its 36% year on operations, not a headline. FY26 margins expanded 140 basis points, operational profit grew 50.3%, net debt to EBITDA fell to 1.52 times, and the flagship plant closed a United States inspection at the mildest classification in August 2026.

The offsets are concrete. Half the revenue sits in a slow American market, Alathur is open, and launches are back-ended into FY27. Anyone buying this regulated generics stock here is buying execution, not a discount.

Frequently Asked Questions

Which regulated generics stock rose 36% in 1 year?

Ans. Strides Pharma Science Ltd (NSE: STAR) is the regulated generics stock that rose approximately 36%, from Rs 885.25 on 17 September 2025 to Rs 1,201.40 on 17 September 2026. The verified return is 35.71%, with no split or bonus.

Why did the Strides Pharma share price rise in the last year?

Ans. Margins improved and debt fell. The September 2025 quarter lifted the EBITDA margin 320 basis points to 19% and pushed the regulated generics stock up 15% on 31 October 2025, FY26 results on 18 May 2026 showed operational profit up 50.3%, and a clearance on 20 August 2026 added 11%.

How did the OneSource demerger affect the Strides Pharma share price?

Ans. It removed the contract manufacturing and soft gelatin businesses, so the share fell from around Rs 1,635 in late November 2024 to Rs 682.55 around the 6 December 2024 record date. Holders received one OneSource share for every two Strides shares.

What is the current USFDA status of Strides Pharma plants?

Ans. The Bengaluru facility received an Establishment Inspection Report on 20 August 2026 with a Voluntary Action Indicated classification, closing a May 2026 inspection that carried five observations. The Alathur plant was inspected in early September 2026 and got a Form 483 with three open observations.

How much debt has Strides Pharma reduced?

Ans. Consolidated borrowings fell from roughly Rs 3,030 crore in FY23 to Rs 1,758 crore in FY26. Net debt was Rs 1,424.6 crore in June 2026, net debt to EBITDA improved to 1.52 times from 1.9 times, and net debt to equity is 0.43 times.

What were the Strides Pharma Q1 FY27 results?

Ans. June 2026 quarter revenue was Rs 1,265.4 crore, up 13%, with gross margin at 60.9%. EBITDA rose about 5% to Rs 229.8 crore while the margin slipped to 18.2%. Operational profit was Rs 123.1 crore and reported profit Rs 165.5 crore, including a Rs 100 crore divestment gain.

Is there a verified Strides Pharma share price target?

Ans. No brokerage Strides Pharma share price target published after the June 2026 quarter could be verified, so no forecast is offered for this regulated generics stock. Views compiled before the May 2026 results sat between roughly Rs 1,080 and Rs 1,250, a band the price has passed.

What are the main risks in this regulated generics stock?

Ans. The largest risks in this regulated generics stock are American pricing pressure on a market that is half of revenue and grew 2% in FY26, the unresolved Form 483 at Alathur, and small-cap volatility that took it from Rs 768.65 to Rs 1,231 in four months.